In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of developing oral mucositis with mean incidence of 80-100%.
It is estimated that 89.0%-100.0% of the population undergoing head and neck chemotherapy will develop oral mucositis. In addition there are >4M stage 3-4 cancer patients worldwide (>1m in U.S.) that are receiving high doses of CT or a combination of CT/RT that develop OM 1.0%-53.0% of the time.
The current status of Oral mucositis (OM) treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and palifermin, and a growth factor. None of these products have been completely successful in treating OM and a high unmet medical need exists.
DelveInsight report on Oral Mucositis gives comparative study of drugs under development. The report provides assessment of AG-013 pipeline drug by ActogeniX NV (Intrexon) which is in Phase II/III. In addition to this, the report imparts information on several other drugs as well, among which 6 are in phase II, 3 in phase I, 3 in pre – clinical and 1 in discovery phase.
Key highlights of the report
- R&D activities and technologies used along with the pipeline molecules in development.
- Information related to collaborations, in-licensing and out-licensing deals.
- Stages of development of pipeline molecules.
- Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
The Oral Mucositis-Pipeline Insights, 2015 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Oral Mucositis-Pipeline Insights helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market.
DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.
For more information on Oral Mucositis-Pipeline Insight Report, email at info@delveInsight.com
DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
The Active Pharmaceutical Ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
DelveInsight API Insights’ focus uncovers the commercial manufacturing status of 1600 Active Pharmaceutical ingredient molecules and above. The Report opens the opportunities for Generic Industries, Drug Companies as well as API Manufacturers to keep them updated on the API front all across the globe. The data in the report will provide you with the strategic move for long term successful business.
DelveInsight is serving thousands of Companies and associated people in decision making in this highly competitive world.
Get the best out of Pharm API. Pharm API guides you at every step of the API buisness leading to successful milestones.
Drug Reports starts from USD 500
Indication Reports starts from USD 1250
- Identification of API Manufacturers for US, Europe, India and China.
- Potential API identification to add into the Company’s product portfolio.
- Global Coverage of API Business Opportunities
- Forecasted drug global sales for 2014-2016
- Modulate production to reflect demand
- Understand current market and growth dynamics
- Estimate patent expiry dates for competitor drugs for your interested indication.
- Analyze the impact of patent expiry and identify drugs that are vulnerable to generic competition.
The reports give deep details on the API and API Manufacturers information across the globe with their patent expiration details and Drug global sales forecasting till 2016. We can also customize these reports on the basis of clients needs. The reports are available on some of the leading market resellers website such as Report Linker/Report Buyer Market Reports Japan, Market Publishers, MarketReserachReports, MarketResearch.com, JSB Market Research, Reportstack and Bharat Book Bureau.
Or you can directly contact us for the Reports by emailing us at email@example.com
“If a market is growing enormously, you need to understand what’s nourishing it”
DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.
Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.
Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.
Five worth Reason for Spending on these Reports
- Track your closest Competitors
- Identifying potential customers
- Prioritizing new drug intermediates to add to the portfolio
- Uncovering opportunities Globally
- Organic as well as Inorganic Growth
Who can buy these Reports?
- Pharma Companies
- Drug Development Companies
- Generic Manufacturing Companies
- API Manufacturers
Where to buy?
DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.
At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.
We DELVEINSIGHT are Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers to Drug Research Companies. We can help you in building clients for your business and can help you in expanding your business while providing you the marketing strategies and therefore enabling you to grow revenue. Our team of experts can analyze your current business practices and streamline your processes to increase your return on investment.
We have our proprietary Pharm Delve Platform for publishing multiple reports specific to Indication, Drug/Drug Classes covering the US, Europe, India, China and all emerging markets.
Currently we have 900+ Reports in the market for Indications and Drugs which can be further customized based on your needs.
Please contact us if you have any specific requirements at firstname.lastname@example.org
You can also visit our website for more information w: www.delveinsight.com